Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Dossier - 20/12/2012 19018_de.jpg

    Medical technology serving healthcare

    Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/medical-technology-serving-healthcare
  • Digitalisation in Medicine - 08/12/2020 Bild-1_Druckergehaeuse.jpg

    DiHeSys takes steps towards application

    Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.

    https://www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
  • Press release - 18/03/2022

    Lung Tissue from the Lab

    Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-tissue-lab
  • Press release - 11/12/2023

    Heidelberg center for personalized medicine achieves the highest quality standards

    The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-personalisierte-medizin-heidelberg-erfuellt-hoechste-qualitaetsstandards
  • Press release - 08/04/2025

    Freiburg cancer researcher receives the German Cancer Award 2025

    Melanie Börries, Professor of Medical Bioinformatics at the Medical Faculty of the University of Freiburg and Director of the Institute of Medical Bioinformatics and Systems Medicine at the Medical Center – University of Freiburg, is being honoured for her pioneering work in personalised cancer therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburg-cancer-researcher-receives-german-cancer-award-2025
  • Article - 07/02/2019 Ein Porträtfoto des Mediziners.

    Artificial intelligence in ophthalmology

    Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
  • Dossier - 10/03/2014 20939_de.jpg

    Cancer therapy and cancer diagnostics

    Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
  • Press release - 25/01/2021

    Protein anchors as a newly discovered key molecule in cancer spread and epilepsy

    Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
  • Press release - 11/02/2025

    New perspectives for personalized therapy of brain tumors

    Scientists from the German Cancer Research Center (DKFZ) and ShanghaiTech University have developed an innovative method for growing brain tumors of individual patients in the laboratory that mimic the original structure and the molecular property of the parental tumor as closely as possible. Drug tests in this model were found to correlate very well with actual patient responses, making it a valuable method for investigating therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-perspectives-personalized-therapy-brain-tumors
  • Dossier - 18/06/2012 import_03860_de.jpg

    Biobanks treasure chests for biomedical research

    The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research
  • Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Nahaufnahme eines Multiplex-Chips mit roten oder blauen Kanälen, der zwischen zwei Fingern in blauen Handschuhen gehalten wird.

    Antibiotic detection from whole blood or exhaled breath possible

    Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
  • AaviGen GmbH: Hope for heart failure - 14/07/2022 Black and white electron microscope image of some virus particles.

    Gene therapy for weakened hearts

    Treating a weak heart – for example after a heart attack – at the GP’s surgery with a single intravenous injection, without causing serious side effects: what sounds almost too good to be true is actually already under development. The Heidelberg-based biotech company AaviGen is working on a platform technology based on adeno-associated viruses that can help introduce therapeutic genes in a highly specific way into diseased heart muscle cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-weakened-hearts
  • Press release - 01/09/2022

    Personalised antibiotic treatment strategies for tuberculosis patients

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
  • Article - 10/06/2021 DSC3962.jpg

    New study: vaccine therapy for treating patients with chronic leukaemia

    Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-study-vaccine-therapy-treating-patients-chronic-leukaemia
  • Personalised medicine - 16/09/2021 Diagram illustrating pharmacogenomics. Individuals with different genetic makeups are shown as different coloured pictograms and have different combinations of efficacy and toxicity. A drawing of an hourglass is used to illustrate the influence of non-genetic factors.

    Pharmacogenomics enables individualised drug prescription

    Every person is unique, and their reaction to medications can be just as individual. For this reason, unexpected side effects occur time and again with common drugs, sometimes with life-threatening consequences. At the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) in Stuttgart, the influence of hereditary factors on these harmful reactions is being investigated in order to enable individualised therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharmacogenomics-enables-individualised-drug-prescription
  • Press release - 13/03/2025

    Dieter Schwarz Foundation provides long-term funding for application-oriented basic research and innovative talent pool

    The Max Planck Society and the Dieter Schwarz Foundation (DSS) have embarked on a groundbreaking initiative. On March 13, 2025, they signed an agreement through which the foundation will support an innovative approach by the Max Planck Institute for Medical Research in Heidelberg to translate basic research findings into practical applications. As part of this endeavour, two new departments of the institute will be established in Heilbronn.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dieter-schwarz-foundation-provides-long-term-funding-application-oriented-basic-research-and-innovative-talent-pool
  • Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024 Das Bild zeigt eine mikroskopische Aufnahme eines Gewebes. Die Aufnahme ist bunt und unterschiedliche Zelltypen lassen sich deutlich erkennen.

    Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence

    Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Comprehensive-histological-diagnostics-through-high-dimensional-imaging-and-artificial-intelligence
  • Press release - 13/06/2024

    Eyesight from a 3D Printer

    Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eyesight-3d-printer
  • Press release - 20/11/2024

    Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery

    The German Federal Ministry of Education and Research (BMBF) is currently funding a project at the Department of Oral and Maxillofacial Surgery at Heidelberg University Hospital with around 1.2 million euros. The aim is to use 3D printing technology to produce individualized implants directly in the clinic, thus enabling faster, more efficient and more precise patient-specific care. To this end, the UKHD is working with an industrial partner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/millions-federal-funding-customized-3d-printing-patients-oral-and-maxillofacial-surgery
  • Dossier - 05/11/2012 18550_de.jpg

    Cancer basic research successes and trends

    Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
  • Development of the genomDE genome database - 04/12/2020 national-cancer-institute-to8o0bqOA6Q-unsplash.jpg

    Whole genome sequencing for diagnosing rare diseases

    Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…

    https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
  • Reduced immunosuppression possible in transplantations - 05/06/2023 Group photo of the founding team. Two younger men in light blue shirts and short hair and a woman with long dark hair in a white turtleneck jumper can be seen.

    Modified immune cells produce donor-specific tolerance

    Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modified-immune-cells-produce-donor-specific-tolerance
  • Predicting the success of cancer treatment - 20/06/2023 Graphical representation of the course of intestinal microbiome analysis in CAR-T cell therapy patients.

    Focusing on gut microbiome for CAR T-cell therapy

    Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search